-
Article
Open AccessPharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
To determine whether molecular parameters could be partly responsible for resistance or sensitivity to oxaliplatin (OX)-based chemotherapy used as first-line treatment in advanced colorectal cancer (CRC). We s...
-
Article
Open AccessErratum: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
Correction to: British Journal of Cancer (2008) 99, 1050–1055. doi:10.1038/sj.bjc.6604671 Upon publication of the above manuscript in Volume 99 of BJC, the authors noted a small error in the affiliations of L ...
-
Article
Open AccessInvestigation of a possible extended risk haplotype in the IL23R region associated with ankylosing spondylitis
The IL23R region on chromosome 1 exhibits complex associations with ankylosing spondylitis (AS). We used publicly available epigenomic information and historical genetic association data to identify a putative re...
-
Article
Open AccessPembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously...